(Q56986316)

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.158

Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.158

Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.158

Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.158

Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.158

Biomedicine. Lowering LDL--not only how low, but how long?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.158

Stone agers in the fast lane: chronic degenerative diseases in evolutionary perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.158

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.158

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.158

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.158

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.158

Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuv

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.158

The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.158

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.158

Usefulness of childhood non-high density lipoprotein cholesterol levels versus other lipoprotein measures in predicting adult subclinical atherosclerosis: the Bogalusa Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.158

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.158

The things to come of SHAPE: cost and effectiveness of cardiovascular prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.158

Risks of statin use during pregnancy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.158

General cardiovascular risk profile for use in primary care: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.158

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.158

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.158

Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.158

Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.158

Long-term follow-up of the West of Scotland Coronary Prevention Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.158

The Masai of East Africa: some unique biological characteristics.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22045046

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22045046